Results 171 to 180 of about 178,048 (244)

A Highly Sensitive BRET-Based Reporter for Live-Cell Detection of HIV-1 Protease Activity and Inhibitor Screening. [PDF]

Viruses
Centazzo M, Djossou AV, Pavan S, Alvisi G.   +3 more
europepmc   +1 more source

Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance. [PDF]

Chem Commun (Camb), 2022
Ghosh AK, Weber IT, Mitsuya H.
europepmc   +1 more source

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1223-1234, May 2026.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source

Factors Influencing the Binding of HIV-1 Protease Inhibitors: Insights from Machine Learning Models. [PDF]

ChemMedChem
Shalit Y, Tuvi-Arad I.
europepmc   +1 more source

HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues. [PDF]

Eur J Med Chem, 2023
Lockbaum GJ, Rusere LN, Henes M, Kosovrasti K, Rao DN, Spielvogel E, Lee SK, Nalivaika EA, Swanstrom R, Yilmaz NK, Schiffer CA, Ali A.   +11 more
europepmc   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1205-1215, May 2026.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Ligand Versatility and Resistance Mechanism of Monotherapy-Grade HIV-1 Protease Inhibitor GRL-142 Binding the Multidrug Resistant Variant p51: Insights from 1 μs MD Simulations. [PDF]

J Chem Inf Model
Arias A, Cappelli C, Restrepo A, Alí-Torres J, Gómez S.   +4 more
europepmc   +1 more source

A Triterpenoid‐Enriched GLE70 Fraction From Ganoderma lingzhi Ameliorates Alcoholic Liver Disease via Multi‐Target Regulation

Food Science &Nutrition, Volume 14, Issue 5, May 2026.
GLE fractions were prepared from Ganoderma lingzhi using gradient ethanol elution and evaluated for their biological activities. Among the fractions, GLE70 exhibited the strongest antioxidant and hepatoprotective effects. Integrated chemical characterization, network pharmacology, molecular docking, and in vivo validation suggested that GLE70 may exert
Yanjun Chen, Wenjia Li, Shiyi Ye, Jiaxue Li, Xiaobing Song, Qianli Ma, Ping Chen, Biying Zhang   +7 more
wiley   +1 more source

Integrative Computational Approaches for Understanding Drug Resistance in HIV-1 Protease Subtype C. [PDF]

Viruses
Venkatachalam S, Muralidharan N, Pandian R, Sayed Y, Gromiha MM.   +4 more
europepmc   +1 more source

Evaluation of darunavir-derived HIV-1 protease inhibitors incorporating P2' amide-derivatives: Synthesis, biological evaluation and structural studies. [PDF]

Bioorg Med Chem Lett, 2023
Ghosh AK, Shahabi D, Kipfmiller M, Ghosh AK, Johnson M, Wang YF, Agniswamy J, Amano M, Weber IT, Mitsuya H.   +9 more
europepmc   +1 more source